id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-1523-0035,FDA,FDA-2013-N-1523,Letter from FaegreBD Consulting,Other,Letter(s),2014-05-12T04:00:00Z,2014,5,2014-05-12T04:00:00Z,,2014-05-12T18:05:47Z,,0,0,09000064816d8d1f
FDA-2013-N-1523-0034,FDA,FDA-2013-N-1523,Supplement from Auxilium Pharmaceuticals Inc. Hogan Lovells US LLP,Other,Supplement (SUP),2014-05-07T04:00:00Z,2014,5,2014-05-07T04:00:00Z,,2014-05-07T18:29:49Z,,0,0,09000064816be5ae
FDA-2013-N-1523-0001,FDA,FDA-2013-N-1523,"Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Request for Nominations",Proposed Rule,Request for Information,2013-12-04T05:00:00Z,2013,12,2013-12-04T05:00:00Z,2014-03-05T04:59:59Z,2014-03-11T01:02:11Z,2013-28980,0,0,09000064814a61e6